InsidersTradesSigma
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Insider track record
OtherDisclosed buys
3
Disclosed sells
0
T+90 hit rate
20%
T+90 mean return
-0.0%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Bleil Lynn Dorsey. Officer active across 3 companies, notably Amicus Therapeutics, INC.. Cumulatively, 9 reports have been logged. Split: 3 buys · 0 sell. Total volume traded: €408k. History available since 25 May 2021. The latest transaction was disclosed on 4 November 2024 (Disposition). Regulator: SEC (Form 4). The full history is free.
Declarations9 total
2,465 shares@ US$62.00100.0% of flowCommon StockSEC:0001415889-24-026024:0
11,847 shares0Common StockSEC:0000950170-24-071006:0
8,584 shares0Common StockSEC:0001209191-23-036425:0
12,671 shares0Common StockSEC:0001209191-22-035821:0
10,115 shares0Common StockSEC:0001209191-21-040390
10,115 shares0Common StockSEC:0001209191-21-040390:0
28,605 shares@ US$8.740.0045% mcap50.0% of flowCommon StockSEC:0001209191-21-036239:0
Ideal exit: 19 Feb 2022 (T+270)
28,605 shares@ US$8.7450.0% of flowCommon StockSEC:0001209191-21-036239
Ideal exit: 19 Feb 2022 (T+270)
1,500 sharesCommon StockSEC:0001246360-16-004424:0
Ideal exit: 7 Nov 2016 (T+270)
9 of 9 declarations
About Bleil Lynn Dorsey
Lynn Dorsey Bleil is a director at Amicus Therapeutics, INC.
